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Abstract
Aims: To compare the prevalence of diabetic retinopathy (DR) in people of various ethnic groups with diabetes in the
United Kingdom (UK).
Methods: The Diabetic Retinopathy In Various Ethnic groups in UK (DRIVE UK) Study is a cross-sectional study on the ethnic
variations of the prevalence of DR and visual impairment in two multi-racial cohorts in the UK. People on the diabetes
register in West Yorkshire and South East London who were screened, treated or monitored between April 2008 to July
2009 (London) or August 2009 (West Yorkshire) were included in the study. Data included age, sex, ethnic group, type of
diabetes, presenting visual acuity and the results of grading of diabetic retinopathy. Prevalence estimates for the ethnic
groups were age-standardised to the white European population for comparison purposes.
Results: Out of 57,144 people on the two diabetic registers, data were available on 50,285 individuals (88.0%), of these 3,323
had type 1 and 46,962 had type 2 diabetes. In type 2 diabetes, the prevalence of any DR was 38.0% (95% confidence
interval(CI) 37.4% to 38.5%) in white Europeans compared to 52.4% (51.2% to 53.6%) in African/Afro-Caribbeans and 42.3%
(40.3% to 44.2%) in South Asians. Similarly, sight threatening DR was also significantly more prevalent in Afro-Caribbeans
(11.5%, 95% CI 10.7% to 12.3%) and South Asians (10.3%, 9.0% to 11.5%) compared to white Europeans (5.5%, 5.3% to
5.8%). Differences observed in Type 1 diabetes did not achieve conventional levels of statistical significance, but there were
lower numbers for these analyses.
Conclusions: Minority ethnic communities with type 2 diabetes in the UK are more prone to diabetic retinopathy, including
sight-threatening retinopathy and maculopathy compared to white Europeans.
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Introduction
Diabetic retinopathy (DR) is the most common microvascular
complication of diabetes. Visual loss from diabetic retinopathy
results primarily from two complications. New vessels grow on the
retina; this is known as proliferative retinopathy and accounts for
the majority of severe visual loss. In addition, retinal blood vessels
can become permeable and cause swelling of the centre of the
retina, called diabetic macular oedema. Clinically significant
macular oedema is a leading cause of moderate visual loss in
diabetes. Proliferative retinopathy, severe non-proliferative reti-
nopathy and clinically significant macular oedema can be
considered as sight threatening retinopathy. The established risk
factors of DR include prolonged exposure to hyperglycaemia and
hypertension. However, DR can progress despite optimal control
of these risk factors [1].
Ethnicity is considered a complex risk factor of diabetes. Type 2
diabetes is estimated to be three to four times more common in
people of Asian and African–Caribbean origin compared to white
Europeans [2]. The current population in most metropolitan cities
in UK is ethnically diverse [3], but differs in relative proportions of
ethnic origins when compared to the US population, where
contemporary comparative data on the prevalence of diabetic
retinopathy in multiethnic cohorts are available [4,5]. The
healthcare system in the UK also differs from that in the US. So
it is useful to obtain ethnicity specific estimates of DR in the UK to
understand the impact of the changing population trends on the
prevalence of DR.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32182The aim of this study was to compare the prevalence of diabetic
retinopathy in the three main ethnic groups in the UK- white
Europeans, African/Afro-Caribbeans and South Asians. In order
to obtain a nationally representative sample of people with
diabetes, the prevalence was estimated in two multiracial cohorts
in the UK from the North and South of England- West Yorkshire
and South East London.
Methods
The study was approved by the Chair of the Research Ethics
Committee at King’s College Hospital NHS Foundation Trust
and the London School of Hygiene and Tropical Medicine. As
anonymised datasets were used, the need for individual patient
consent was waived by the committee.
Study population
Anonymised datasets on people with diabetes in the multi-racial
communities in West Yorkshire and South East London were
analysed in this study. The ethnic minority in West Yorkshire is
mainly South Asians while Afro-Caribbeans represent the
predominant minor ethnic group in South East London. People
who are ascertained to have diabetes by their family practitioner
are referred to the local DR screening service for annual screening
as part of the nationwide DR screening programme. These digital
photographic DR screening programmes in the UK are well-
established and 100% of people with diabetes are offered screening
and the uptake rates are at least 80% [6]. Individuals with screen-
positive disease are referred to specified hospital eye services for
further management so it is possible to collate the retinopathy data
on all people with diabetes subject to utilization of these services.
All subjects in the diabetic screening register of both these
programmes were included in this study to provide a reasonably
comprehensive coverage of diabetic people in the respective
regions (95% In West Yorkshire and 81% in South East London).
Demographic data collected include age, sex, ethnic group and
type of diabetes. Self-reported ethnicity based on UK census
standard for classifying the ethnic composition of the communities
were recorded at the time of screening according to the codes used
in the Census 2001 and then categorised into ‘White European’,
‘African/Afro-Caribbean’, ‘South Asian’, ‘Mixed’, ‘other ethnic
group’ and ‘not known’. Effort was made to obtain ethnicity data
from hospital services and primary care records for missing
ethnicity records within the screening programmes before the
records were anonymised.
Screening and grading of diabetic retinopathy
As part of the annual screening procedure per subject, 2-field
digital photographs are taken per eye, one centred on the optic
disc and the other on the macula after dilation of the pupils.
Photographs undergo primary and secondary grading and, if
necessary, are subjected to a final arbitration grading process
according to English Diabetic Retinopathy guidance recom-
mended by the National Screening Programme for Diabetic
Retinopathy (table 1) [6,7]. All referrals of ‘screen positive’ patients
(R2, R3 and M1) were graded by retinal specialists before referral
to the ophthalmology department. The retinopathy grades
obtained by slit lamp biomicroscopy or indirect ophthalmoscopy
were recorded for people for whom it was technically difficult to
acquire retinal photographs. The records of people who were
exempted from the screening programme because they are under
the care of the specified hospital eye service or are blind were
collated from hospital records and the registers for visually
impaired.
The number of people for whom no records were obtainable
was noted, but no further details on the eye condition or ethnicity
could be obtained. In addition, there may be people with very
recently diagnosed diabetes (less than 12 weeks from referral as
newly diagnosed diabetes) or who have only recently registered
with family practices in the area, who have not been included.
We estimated the prevalence of: (a) any DR (R1, R2 and R3) (b)
diabetic maculopathy (M1) (c) clinically significant macular
oedema treated with laser photocoagulation (M1 P1) and (d) sight
threatening diabetic retinopathy (R2, R3 or M1P1). These
categories provided the closest comparison to studies that used
the International classification of diabetic retinopathy scale and
the Early Treatment Diabetic Retinopathy Study (ETDRS) levels
[8,9].
The data analysis was performed using Stata version 11.0 (Stata
Corp., College Station, TX, USA). Data were analysed at the
person level. The eye with the more severe grade of retinopathy
was used in the analyses. Descriptive analyses included reporting
the prevalence of the different diabetic retinopathy grades in type
1 and 2 diabetes in the three target ethnic groups. Prevalence
estimates for the different ethnic groups were directly standardised
to the white population which comprised the largest group.
Logistic regression analyses, including terms for age (continuous),
gender (male/female), diabetes (type 1/type 2), ethnic groups
(white European, African/Afro-Caribbean, South Asians) and
location (South London/West Yorkshire),were used to assess the
independent association between factors and risk of any diabetic
retinopathy, clinically significant macular oedema and prolifera-
tive diabetic retinopathy.
Results
There were 20,878 people with known diabetes on the diabetes
register of West Yorkshire region in August 2009 and 36,266 in
South East London in July 2009. The total population in these
areas in 2009–2010 was estimated to be 534,883 and 868,322
respectively [3]. Thus, the prevalence of diagnosed diabetes in the
two study areas combined is 4.1% which is similar to the average
national prevalence of diagnosed diabetes (4%). Table 2 compares
the estimates of diagnosed diabetes in the study areas with the
Association of Public Health Observatory model of the prevalence
of diagnosed and undiagnosed diabetes [3]. This suggests that
undiagnosed diabetes is highest in the Asian population.
Data on diabetic retinopathy were available in 50,285 (88.0%)
people (figure 1). Table 3 shows the characteristics of the people
with data on diabetic retinopathy. The mean age of the population
with type 1 diabetes was 39.4616.3 years while that of type 2 was
63.6613.3 years. Approximately 63% of people with type 2
diabetes were aged 60 years and over. A greater proportion of
people with type 2 diabetes were of non-white origin compared to
type 1 diabetes.
The prevalence of diabetic retinopathy in the three ethnic
groups is shown in tables 4 and 5. In type 1 diabetes, there were
some differences between the ethnic groups but these differences
were largely not statistically significant due to the small number of
people in some groups. In type 2 diabetes, the prevalence of any
DR was significantly higher in the African/Afro-Caribbean group
(52.4%, 95% confidence intervals (CI)51.2% to 53.6%) and South
Asians (42.3%, 95% CI 40.3% to 44.2%) compared to white
Europeans (38%, 95% CI 37.4% to 38.5%). Clinically significant
macular oedema was nearly three times more common in
African/Afro-Caribbean (10.1%, 95% CI 9.4% to 10.8%) and
twice as prevalent in South Asians (7.1%, 95% CI 6.0% to 8.1%)
compared to white Europeans 3.7% (95% CI 3.5%to 3.9%) . Sight
Ethnicity and Diabetic Retinopathy
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non-white ethnic groups (table 5).
Logistic regression analyses showed that the risk of diabetic
retinopathy, sight threatening diabetic retinopathy and clinically
significant macular oedema increased with increasing age. Women
and people with type 2 diabetes had a lower risk of diabetic
retinopathy compared to men and people with type 1 diabetes
respectively. Minority ethnic groups (both South Asians and
African/Afro-Caribbeans) had increased odds of having retinop-
athy compared to their white counterparts. There were differences
between the locations in prevalence of diabetic retinopathy but
these were not consistent (table 6).
Data stratified by age shows that prevalence of any DR
increases proportionately with age for each racial group and the
prevalence is higher in the minority ethnic groups at all ages.
However, no age related increase in prevalence for sight
threatening diabetic retinopathy and clinically significant macular
oedema were observed in any of the ethnic groups although the
prevalence was higher in African/Afro-Caribbeans and South
Asians (data not shown).
Discussion
The DRIVE UK study is the largest cross-sectional study on the
prevalence of DR in the various ethnic groups with diabetes in the
UK. The study shows that the prevalence of any retinopathy in
type 2 diabetes is highest in people of African/Afro-Caribbean
descent compared to South Asians or white Europeans. Both
South Asians and African/Afro-Caribbeans have about double the
prevalence of clinically significant macular oedema and sight
threatening diabetic retinopathy compared to the white Europe-
ans. There were differences in diabetic retinopathy between the
ethnic groups in type 1 diabetes but these are not statistically
significant due to the small number of people in the study sample.
This study consisted of people with diabetes in two community-
based diabetic retinopathy screening programmes, one represent-
Table 1. Disease grading protocol in National Guidelines on Screening for Diabetic retinopathy grading in England and Wales
screening programmes.
Level Equivalent disease severity level
9 Clinical features
Retinopathy
R0 No retinopathy
R1 Mild and moderate non-proliferative diabetic retinopathy Microaneurysms; retinal haemorrhages or exudates not within the definition
of maculopathy
R2 Severe non-proliferative diabetic retinopathy Venous beading/loop/reduplication;intraretinal microvascular abnormality
;multiple deep, round or blot haemorrhages
R3 Proliferative diabetic retinopathy New vessels disc or elsewhere
Maculopathy
M0 No maculopathy
M1 Exudate within 1 disc diameter of the centre of the fovea; circinate or group
of exudates within the macula; retinal thickening within 1 disc diameter of
the centre of the fovea; any microaneurysm or haemorrhage within 1 disc
diameter of the centre of the fovea only if associated with a best visual acuity
of 6/12 or worse.
Photocoagulation
P0 No photocoagulation
P1 Evidence of focal or grid laser or peripheral scatter
Unclassifiable
U Unobtainable/ungradable
9International classification proposed by American Academy of Ophthalmologists.
doi:10.1371/journal.pone.0032182.t001
Table 2. Estimated prevalence of diabetes (type 1 and type 2) in the two study areas combined in 2009–2010.
Ethnic group
Number of people estimated
to be resident in two study
areas combined
a
Current study: % of population
currently on the diabetic register
(number of people)
YHPO model: estimated % of population
with diagnosed or undiagnosed diabetes
in two study areas combined
b
(number of people)
White Europeans 980,992 3.4 (33,009) 6.7 (65,603)
African-Caribbean 177,222 4.7 (8,376) 9.1 (16,151)
South Asian 81,649 4.3 (3,518) 14.1 (11,512)
aData source: Office of National Statistics: http://www.statistics.gov.uk/statbase/Product.asp?vlnk=601. Accessed August 2011.
bEstimated by the Yorkshire and Humberside Public Health Observatory model, including diagnosed and undiagnosed diabetes in the community. http://www.yhpho.
org.uk/resource/view.aspx?RID=78382 Accessed August 2011.
doi:10.1371/journal.pone.0032182.t002
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and the other reflecting regions within UK with pockets of minor
ethnic groups (West Yorkshire). Of the 57,144 people diagnosed
with diabetes in the two regions, data on DR was available in
50,285 (88.0%) which is comparable to the response rates of other
population-based studies.
The prevalence of diagnosed diabetes in this study is 4.1% with
similar rates of diagnosed diabetes between the three ethnic
groups. Although the public health model in UK [2] shows a
disproportionate burden of diabetes in South Asians and African/
Afro-Caribbeans, this study suggests that undiagnosed diabetes
and/or uptake of retinal screening remain an issue especially in the
minor ethnic groups in the UK.
The overall prevalence of diabetic retinopathy in type 1 diabetes
was 53.1%, clinically significant macular oedema of 8.9% and
sight threatening diabetic retinopathy of 14.4%. Although there is
no historical comparative data in the UK, it is reassuring to note
that the prevalence in this population is very similar to that
observed in the Nordic countries (41.8% diabetic retinopathy and
12.1% sight threatening diabetic retinopathy) [10] where there is
overwhelming evidence of a decline in the incidence of sight
threatening diabetic retinopathy compared to reports published
two decades ago [11,12].
In type 2 diabetes, the overall prevalence of diabetic retinopathy
was 39.5%, of clinically significant macular oedema was 4.7% and
sight threatening diabetic retinopathy was 8.3% in keeping with
estimates generated by other contemporary studies in the US and
UK [4–5]; [13–14]. The prevalence of diabetic retinopathy in UK
has remained constant over last two decades despite the global
increase in the prevalence of diabetes [15], the changing
population composition and the improved diagnostic criteria and
examination techniques.
Studies conducted before the UKPDS era that compared the
prevalence of diabetic retinopathy between African/Afro-Carib-
bean and white Europeans in the UK did not reveal significant
differences between the two groups [16,17]. However, contempo-
rary comparative data in the US show higher rates in people on
African descent [18–21]. Both the ARIC [19] and MESA [5]
studies noted that these differences were negated when other risk
factors for diabetic retinopathy were included in the regression
model. This study did not assess other risk factors of diabetic
retinopathy such as duration of diabetes, control of hyperglycemia,
hypertension and smoking status that may further help define the
differences in prevalence between these ethnic groups.
The strength of our study is the use of a substantial dataset of a
representative multiethnic population with physician diagnosed
diabetes and the use of standard national quality-assurance
protocols for post-mydriatic 2-field high-resolution digital photo-
graphs and grading of diabetic retinopathy.
One limitation of this study is the use of a grading system that is
not universally used in epidemiologic studies making it difficult to
compare the prevalence of clinically significant macular oedema.
However, the prevalence of diabetic retinopathy in type 2 diabetes
in the white population in this study (38%) was similar to that
found other recent studies in the world that used either the interim
or final ETDRS levels. Secondly, this study is limited to those who
attend screening and treatment for DR so it likely that the rates
may be an underestimation. Additionally, we have not considered
retinopathy rates in people with undiagnosed diabetes. Although
we have adjusted for age, gender, type of diabetes, ethnicity and
region, we did not assess other traditional risk factors of diabetic
retinopathy such as glycemic control, blood pressure and duration
of diabetes as it was beyond the scope of this study. It would be
useful to observe whether ethnicity remains an independent risk
Figure 1. Flow chart of participants in the study.
doi:10.1371/journal.pone.0032182.g001
Table 3. Characteristics of the study population.
Type 1 diabetes
N=3,323
Type 2 diabetes
N=46,962
Mean age (SD) 39.4 (16.3) 63.6 (13.3)
N(%) N(%)
Age ,20 326 (9.8) 23 (0.1)
Age 20–29 748 (22.5) 134 (0.3)
Age 30–39 755 (22.7) 1634 (3.5)
Age 40–49 680 (20.5) 5779 (12.3)
Age 50–59 382 (11.5) 9802 (20.9)
Age 60–69 235 (7.1) 12352 (26.3)
Age 70–79 152 (4.6) 11843 (25.2)
Age 80+ 44 (1.3) 5366 (11.4)
Male 1764 (53.1) 24842 (52.9)
White Europeans 2628 (79.2) 30352 (64.7)
African/Afro-Caribbean 344 (10.4) 8023 (17.1)
South Asian 120 (3.6) 3397 (7.2)
Mixed race 105 (3.2) 2577 (5.5)
Other 123 (3.7) 2587 (5.5)
doi:10.1371/journal.pone.0032182.t003
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should also focus on other potential reasons for these ethnic
differences such as differential susceptibility to risk factors, genetic
and behavioural variations, later diagnosis of diabetes and
differences in access to healthcare including rates of uptake/
compliance with evidence based treatments.
Table 4. Prevalence of retinopathy in people with type 1 diabetes.
Ethnic group Prevalence: N (%) Age-standardised prevalence
a: % (95% CI)
Any diabetic retinopathy (R1 or R2 or R3)
White Europeans 1446 (55.0) 55.0 (53.2,56.9)
African/Afro-Caribbean 154 (44.8) 42.8 (37.3, 48.3)
South Asian 64 (53.3) 54.0 (44.8, 63.2)
Any maculopathy (M1)
White Europeans 371 (14.1) 14.1 (12.8,15.4)
African/Afro-Caribbean 47 (13.7) 13.1 (9.4,16.8)
South Asian 17 (14.2) 16.6 (10.0, 23.2)
CSMO (M1P1)
White Europeans 171 (6.5) 6.5 (5.6, 7.4)
African/Afro-Caribbean 35 (10.2) 10.0 (6.7,13.3)
South Asian 12 (10.0) 11.2 (5.4,16.9)
STDR (R2 or R3 or M1P1)
White Europeans 318 (12.1) 12.1 (10.9,13.3)
African/Afro-Caribbean 53 (15.4) 15.9 (11.8, 20.0)
South Asian 19 (15.8) 17.5 (10.6, 24.3)
aStandardised to the age-structure of the white European population;
Number (missing data on age): White Europeans n=2,628 (0) African/Afro-Caribbean n=344 (1), South Asian n=120 (0).
CSMO- clinically significant macular oedema; M1- maculopathy P1- macular laser; STDR- sight threatening diabetic retinopathy; R1- mild to moderate non-proliferative
diabetic retinopathy; R2- pre-proliferative diabetic retinopathy; R3- Proliferative diabetic retinopathy
doi:10.1371/journal.pone.0032182.t004
Table 5. Prevalence of diabetic retinopathy in people with type 2 diabetes.
Ethnic group Prevalence: N (%) Age-standardised prevalence
a: % (95% CI)
Any diabetic retinopathy (R1 or R2 or R3)
White Europeans 11538 (38.0) 38.0 (37.4, 38.5)
African/Afro-Caribbean 4117 (51.3) 52.4(51.2, 53.6)
South Asian 1350 (39.7) 42.3 (40.3, 44.2)
Any maculopathy (M1)
White Europeans 2249 (7.4) 7.3 (7.1, 7.6)
African/Afro-Caribbean 1037 (12.9) 14.0 (13.2,14.8)
South Asian 396 (11.7) 12.6 (11.2,13.9)
CSMO (M1P1)
White Europeans 1127 (3.7) 3.7(3.5, 3.9)
African/Afro-Caribbean 720 (9.0) 10.1(9.4,10.8)
South Asian 211 (6.2) 7.1(6.0, 8.1)
STDR (R2 or R3 or M1P1)
White Europeans 1680 (5.5) 5.5 (5.3, 5.8)
African/Afro-Caribbean 827 (10.3) 11.5 (10.7,12.3)
South Asian 314 (9.2) 10.3(9.0, 11.5)
aStandardised to the age-structure of the Caucasian population;
Number (missing data on age): White Europeans n=30,350 (20) African/Afro-Caribbean n=8,023 (0) South Asian n=3,397 (8).
CSMO- clinically significant macular oedema; M1- maculopathy P1- macular laser; STDR- sight threatening diabetic retinopathy; R1- mild to moderate non-proliferative
diabetic retinopathy; R2- pre-proliferative diabetic retinopathy; R3- Proliferative diabetic retinopathy.
doi:10.1371/journal.pone.0032182.t005
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West Yorkshire 1 1 1 1
South East London 0.91 (0.87, 0.94) 0.69 (0.63, 0.77) 1.79 (1.61, 1.99) 1.04 (0.96,1.13)
Type I diabetes 1 1 1 1
Type 2 diabetes 0.47 (0.43, 0.51) 0.32 (0.27, 0.37) 0.42 (0.35, 0.49) 0.35 (0.31, 0.40)
White Europeans 1 1 1 1
African/Afro-Caribbeans 1.79 (1.70, 1.89) 1.61 (1.42, 1.82) 2.12 (1.91, 2.35) 1.99 (1.81,2.18)
South Asians 1.10 (1.02, 1.18) 1.52 (1.31, 1.77) 1.98 (1.71, 2.30) 1.82 (1.61, 2.06)
Other 0.75 (0.70, 0.80) 0.59 (0.48, 0.72) 0.68 (0.57, 0.81) 0.68 (0.58, 0.79)
*Adjusted for all factors on the table.
CSMO- clinically significant macular oedema; R1- Mild to moderate non-proliferative diabetic retinopathy; R2- Severe non-proliferative diabetic retinopathy; R3-
Proliferative diabetic retinopathy; M1P1- laser treated diabetic maculopathy; STDR-sight threatening diabetic retinopathy.
doi:10.1371/journal.pone.0032182.t006
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